Aim: To report on the use of a combined intra-ocular tamponade with silicone oil and perfluorohexyloctane (F6H8) in the treatment of complex retinal detachment. Design: A prospective consecutive interventional case series from seven study centres. Participants: 69 patients presenting a retinal detachment with proliferative vitreoretinopathy (PVR) and retinal breaks of the inferior two quadrants of the fundus. Method: Patients were divided into two groups: (1) 28 eyes which had not been operated on before; (2) 41 eyes affected by recurrent retinal detachment that had had unsuccessful previous surgery with silicone oil or gas tamponade. A pars plana vitrectomy, membrane peeling and – when necessary – a retinotomy were performed; the vitreous cavity was filled with two thirds of F6H8 and one third of silicone oil 1,000 mPas (double filling, DF). The endotamponade was removed after 30–45 days (median 38) and replaced by balanced salt solution or silicone oil according to the condition of the retina. Results: Retinal reattachment was achieved in 52 out of 69 cases (75%) 6 months after removal of the DF without any endotamponade. Conclusion: The DF with F6H8 and silicone oil allows a good endotamponading to the inferior retina and the posterior pole. The DF appeared to be well tolerated. Further studies are necessary to evaluate whether a DF is advantageous in respect to silicone oil filling alone in case of retinal breaks and PVR of the inferior retina.

Keywords:
Long-term vitreous replacement, Perfluorohexyloctane (F6H8), Silicone oil
1.
Peyman GA, Conway MD, Soike KF, Clark LC: Long-term vitreous replacement in primates with intravitreal Vitreon or Vitreon plus silicone. Ophthalmic Surg 1991;22:657–664.
2.
De Molfetta V, Bottoni F, Arpa P, Vinciguerra P, Zenoni S: The effect of simultaneous internal tamponade on fluid compartmentalization and its relationship to cell proliferation. Retina 1992;12:S40–S45.
3.
Sparrow JR, Jayakumar A, Berrocal M, Ozmert E, Chang S: Experimental studies of the combined use of vitreous substitutes of high and low specific gravity. Retina 1992;12:134–140.
4.
Orzalesi N, Migliavacca L, Bottoni F, Miglior S: Experimental short-term tolerance to perfluorodecalin in the rabbit eye: A histopathological study. Curr Eye Res 1998;17:828–835.
5.
Zeana D, Becker J, Kuckelkorn R, Kirchhof B: Perfluorohexyloctane as a long-term vitreous tamponade in the experimental animal: Experimental perfluorohexyloctane substitution. Int Ophthalmol 1999;23:17–24.
6.
Kirchhof B: Fluorcarbone in der Netzhaut-Glaskörperchirurgie. Ophthalmochirurgie 1999;11:153–158.
7.
Kirchhof B, Wong D, Van Meurs J, Hilgers RD, Macek M, Lois N, Schrage NF: Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery. Am J Ophthalmol 2002;133:95–101.
8.
Hiscott P, Magee RM, Colthurst M, Lois N, Wong D: Clinicopathological correlation of epiretinal membranes and posterior lens opacification following perfluorohexyloctane tamponade. Br J Ophthalmol 2001;85:179–183.
9.
Rizzo S, Genovesi-Ebert F, Belting C: The combined use of perfluorohexyloctane (F6H8) and silicone oil as an intraocular tamponade in the treatment of severe retinal detachment. Graefes Arch Clin Exp Ophthalmol, accepted.
10.
Genovesi-Ebert F, Rizzo S, Figus M, Ferretti C, Nardi M: Combination of silicone solvent (F6H8) and PDMS in complex retinal detachment. IOVS 2000;41:3521.
11.
Anonymous: The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983;90:121–125.
12.
Rivara A, Zingirian M: Rilievi biometrici sulla lunghezza dei vari assi oculari e sul volume del bulbo eseguiti col metodo ecografico. Ann Oftalmol Clin Ocul 1965;91:1233–1238.
13.
Mertens S, Bednarz J, Engelmann K: Evidence of toxic side effects of perfluorohexyloctane after vitreoretinal surgery as well as in previously established in vitro models with ocular cell types. Graefes Arch Clin Exp Ophthalmol 2002;240:989–995.
14.
Malchiodi-Albedi F, Matteucci A, Formisano G, Paradisi S, Carnovale-Scalzo G, Perilli R, Scorcia G, Caiazza S: Perfluorohexyloctane (F6H8) induces structural modifications and increases apoptosis in rat primary retinal cultures. J Biomed Mater Res 2003;65B:133–136.
15.
Herbert E, Stappler T, Wetterquist C, Williams R, Wong D: Tamponade properties of double-filling with perfluorohexyloctane and silicone oil in a model eye chamber. Graefes Arch Clin Exp Ophthalmol 2004;242:250–254.
16.
Roider J, Hoerauf H, Kobuch K, Gabel VP: Clinical findings on the use of long-term heavy tamponades (semifluorinated alkanes and their oligomers) in complicated retinal detachment surgery. Graefes Arch Clin Exp Ophthalmol 2002;240:965–971.
17.
Fleury J, Bonnet M: Prognostic value of new retinal tears associated with the development of postoperative proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1992;230:459–462.
18.
Cox MS, Trese MT, Murphy PL: Silicone oil for advanced proliferative vitreoretinopathy. Ophthalmology 1986;93:646–650.
19.
Bottoni F, Arpa P, Vinciguerra P, Zenoni S, De Molfetta V: Combined silicone and fluorosilicone oil tamponade (double filling) in the management of complicated retinal detachment. Ophthalmologica 1992;204:77–81.
20.
Jonas JB, Knorr HLJ, Rank RM, Budde WM: Retinal redetachment after removal of intraocular silicone oil tamponade. Br J Ophthalmol 2001;85:1203–1207.
21.
Gremillio CM Jr, Peyman GA, Liu KR, Naguib KS: Fluorosilicone oil in the treatment of retinal detachment. Br J Ophthalmol 1990;74:643–646.
22.
Stefaniotou MI, Aspiotis MV, Kitsos GD, Kalogeropoulos CD, Asproudis IC, Psilas KG: Our experience with perfluorohexyloctane (F6H8) as a temporary endotamponade in vitreoretinal surgery. Eur J Ophthalmol 2002;12:518–522.
23.
Tanji TM, Peyman GA, Mehta NJ, Millsap CM: Perfluoroperhydrophenanthrene (Vitreon) as a short-term vitreous substitute after complex vitreoretinal surgery. Ophthalmic Surg 1993;24:681–685.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.